IDegLira success in Phase III trial for Type 2 Diabetes
Phase III data from the investigational therapy IDegLira [Tresiba (insulin degludec)/Victoza (liraglutide injection)] from Novo Nordisk,were presented at the 49th Annual European Association for the Study of Diabetes (EASD) Congress. Data from the DUALT I trial show IDegLira demonstrates a statistically significant greater reduction in blood sugar levels (HbA1c) compared to insulin degludec or liraglutide alone, with no weight gain and a low rate of hypoglycaemia compared to insulin degludec in adults with Type 2 Diabetes. These results were also supported by data showing once-daily IDegLira provides statistically greater reductions in postprandial glucose following all three main meals of the day (breakfast, lunch and dinner) compared to insulin degludec.
IDegLira is a once-daily, single-administration basal insulin/GLP-1 analogue combination being developed for the treatment of Type 2 Diabetes in adults.
See- Gough SCL, et al. "IDegLira, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, is Efficacious and Safe in Subjects with Type 2 Diabetes: A Large, Randomized Phase 3 Trial."- Oral presentation (OP 37) at the 49th Annual European Association for the Study of Diabetes (EASD) Congress, 27 September 2013.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)